| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC0507 |
| Trial ID | NCT04163575 |
| Disease | Lymphoma | Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL |
| Year | 2019 |
| Country | China |
| Company sponsor | Kecellitics Biotech Company Ltd |
| Other ID(s) | Kece-2 |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||